Pular para o conteúdo

Lilly's Retatrutide Beat Ozempic 2 mg on Blood Sugar and Weight Loss in Head-to-Head Diabetes Trial

29 de outubro de 2026 · 16 min

Notas do episódio

Eli Lilly says its investigational once-weekly drug retatrutide beat Novo Nordisk's Ozempic 2 mg in TRANSCEND-T2D-2, the first Phase 3 trial comparing retatrutide head-to-head with another incretin medicine. We walk through the topline results Lilly announced on October 28, 2026 for 1,298 adults with type 2 diabetes not controlled on metformin, with or without an SGLT2 inhibitor: at 80 weeks, A1C fell by an average of 2.2 percentage points on both retatrutide doses (9 mg and 12 mg) versus 1.8 on Ozempic 2 mg, and body weight fell 19.5% and 20.9% versus 9.4%. We explain why only the 12 mg A1C superiority result was statistically controlled while the 9 mg A1C difference was "nominal," that the figures use the efficacy estimand, and that full results have not yet been peer reviewed. We also note what Lilly said about certain cardiovascular risk factors (non-HDL cholesterol, triglycerides and systolic blood pressure) and one Leerink analyst's 2032 sales estimate, and we cover the trade-off: more gastrointestinal side effects and higher discontinuation rates due to adverse events on retatrutide (4.8% and 7.9% versus 2.7% on Ozempic). Retatrutide is not approved anywhere, and Lilly says anyone selling it to consumers is breaking the law. Sources: - Eli Lilly news release, "Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial" (Oct 28, 2026): https://investor.lilly.com/news-releases/news-release-details/lillys-retatrutide-delivered-greater-a1c-reduction-and-more - ClinicalTrials.gov, TRANSCEND-T2D-2 (NCT06260722): https://clinicaltrials.gov/study/NCT06260722 - BioPharma Dive, "Lilly's 'triple-G' drug tops Novo's Ozempic in diabetes trial" (Oct 28, 2026): https://www.biopharmadive.com/news/retatrutide-ozempic-diabetes-trial-results-lilly-novo/873016/ - Reuters via Yahoo News, "Lilly's next-gen drug outshines Ozempic on weight loss, blood sugar control in trial" (Oct 28, 2026): https://www.yahoo.com/news/science/articles/lillys-next-gen-drug-outshines-104705473.html Cover: original illustration made for this episode (three linked spheres beside one); no photo used. This show is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication. Visit glp1newspaper.com to see today's stories and sign up for free email alerts.

Todos os episódios de GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News

Configurações

Exibição

Idioma

Define quais estações você vê primeiro na página inicial.

Histórico

As rádios e episódios ouvidos recentemente e suas últimas buscas ficam só neste navegador.

Avisos

Um aviso rápido quando um podcast que você segue tem um episódio novo. Desative podcasts individuais pelo sino na página deles.

Conta

Salve favoritos – no app e no site.

Atalhos de teclado

/
Abrir busca
Espaço
Reproduzir ou pausar
← →
No player: voltar 15 s, avançar 30 s (episódios) · na fileira: próximo bloco
↑ ↓
Na fileira: alvo dentro do bloco
Home / End
Na fileira: primeiro ou último bloco
Esc
Fechar janela ou menu
?
Esta visão geral
Tocando agora

Ir para a estação

A seguir

    Adicione episódios com “A seguir” – eles tocam depois do episódio atual.